文献速递心境障碍精神分裂症与精神病性障碍焦虑、强迫与应激相关障碍

边缘型人格障碍患者共病人精神病理学的药物干预:Cochrane系统评价与Meta分析的二次分析

Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses.
PubMed 文献 · Br J Psychiatry · 2024-10-21

该研究基于Cochrane系统评价更新检索至2024年3月,纳入22项安慰剂对照试验进行二次分析,评估药物对边缘型人格障碍(BPD)患者共病人精神病理学的疗效。抗精神病药对抑郁症状(SMD -0.22,P=0.04,极低确定性证据)和精神病性-解离症状(SMD -0.28,P=0.007,低确定性证据)有疗效证据;抗惊厥药对抑郁症状(SMD -0.44,P=0.02,低确定性证据)和焦虑症状(SMD -1.11,P<0.00001,极低确定性证据)有疗效证据;抗抑郁药未观察到显著结果(极低确定性证据)。作者结论认为现有极低至低确定性证据不支持使用药物针对BPD共病人精神病理学,药物应谨慎使用。

要点

  • 抗精神病药对抑郁症状有极低确定性证据的疗效(SMD -0.22,P=0.04)。
  • 抗惊厥药对抑郁症状(SMD -0.44,P=0.02,低确定性证据)和焦虑症状(SMD -1.11,P<0.00001,极低确定性证据)有疗效证据。
  • 抗抑郁药未观察到显著结果(极低确定性证据),作者结论不支持用药物针对共病人精神病理学。

核心结论

  • 基于极低和低确定性证据,作者结论不支持使用药物干预针对BPD患者的共病人精神病理学。
  • 现有证据不支持在有无明确共病诊断的样本间存在差异性治疗效果。
  • 药物应谨慎用于针对共病人精神病理学。

研究设计与样本

  • 基于现行Cochrane系统评价,于2024年3月进行更新文献检索,遵循该Cochrane评价方法。
  • 对全部已识别的安慰剂对照试验进行事后审查,筛选报告非BPD特异性(共病)精神病理学的试验。
  • 探索有和无明确共病诊断样本亚组的治疗效果,采用GRADE评级评估证据确定性。
  • 22项试验纳入定量分析。

主要发现

  • 抗精神病药对抑郁症状有极低确定性证据的疗效(SMD -0.22,P=0.04)。
  • 抗精神病药对精神病性-解离症状有低确定性证据的疗效(SMD -0.28,P=0.007)。
  • 抗惊厥药对抑郁症状有低确定性证据的疗效(SMD -0.44,P=0.02),对焦虑症状有极低确定性证据的疗效(SMD -1.11,P<0.00001)。
  • 抗抑郁药未观察到显著结果(极低确定性证据)。
  • 探索性亚组分析提示,在包含共病物质使用障碍参与者的样本中,抗精神病药对精神病性-解离症状的效应更大(P=0.001)。

关键数值与推荐

  • 抗精神病药对抑郁症状:SMD -0.22,P=0.04,极低确定性证据。
  • 抗精神病药对精神病性-解离症状:SMD -0.28,P=0.007,低确定性证据。
  • 抗惊厥药对抑郁症状:SMD -0.44,P=0.02,低确定性证据。
  • 抗惊厥药对焦虑症状:SMD -1.11,P<0.00001,极低确定性证据。
  • 抗抑郁药:未观察到显著结果,极低确定性证据。

临床怎么用

  • 作者结论认为,基于极低和低确定性证据,不支持使用药物干预针对BPD患者的共病人精神病理学。
  • 作者结论认为,药物应谨慎用于针对共病人精神病理学。

局限性

  • 结论仅基于极低确定性和低确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medications are commonly used to treat co-occurring psychopathology in persons with borderline personality disorder (BPD). AIMS: To systematically review and integrate the evidence of medications for treatment of co-occurring psychopathology in people with BPD, and explore the role of comorbidities. METHOD: Building on the current Cochrane review of medications in BPD, an update literature search was done in March 2024. We followed the methods of this Cochrane review, but scrutinised all identified placebo-controlled trials post hoc for reporting of non BPD-specific ('co-occurring') psychopathology, and explored treatment effects in subgroups of samples with and without defined co-occurring disorders. GRADE ratings were done to assess the evidence certainty. RESULTS: Twenty-two trials were available for quantitative analyses. For antipsychotics, we found very-low-certainty evidence (VLCE) of an effect on depressive symptoms (standardised mean difference (SMD) -0.22, P = 0.04), and low-certainty evidence (LCE) of an effect on psychotic-dissociative symptoms (SMD -0.28, P = 0.007). There was evidence of effects of anticonvulsants on depressive (SMD -0.44, P = 0.02; LCE) and anxious symptoms (SMD -1.11, P < 0.00001; VLCE). For antidepressants, no significant findings were observed (VLCE). Exploratory subgroup analyses indicated a greater effect of antipsychotics in samples including participants with co-occurring substance use disorders on psychotic-dissociative symptoms (P = 0.001). CONCLUSIONS: Our findings, based on VLCE and LCE only, do not support the use of pharmacological interventions in people with BPD to target co-occurring psychopathology. Overall, the current evidence does not support differential treatment effects in persons with versus without defined comorbidities. Medications should be used cautiously to target co-occurring psychopathology.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Pereira Ribeiro J, Juul S, Kongerslev MT, et al. Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses. Br J Psychiatry. 2024. PMID: 39428384. doi:10.1192/bjp.2024.172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。